Jefferies Discusses ViroPharma (VPHM) After 2012 Global Healthcare Conference

Jefferies comments ViroPharma (NASDAQ: VPHM) after the company highlighted ongoing development efforts with Cinryze and commented on pipeline progress at the Jefferies 2012 Global Healthcare Conference.

"We continue to believe in the prospects for Cinryze and think that recent weakness creates an attractive entry point for investors ahead of critical catalysts in 2Q (Cinryze sales in July, Cinryze manufacturing expansion approval in August)," the analyst comments.

The firm maintained a Buy rating and $32 price target.

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $20.07 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bark Inc. (BARK) PT Raised to $19 at Jefferies Following 20:1 Reverse Split
• Hanmi Semiconductor Co (042700:KS) PT Raised to KRW200,000 at JPMorgan
• Bernstein SocGen Group Starts Pepsico (PEP) at Market Perform